These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28166459)

  • 1. A Bayesian paradigm for decision-making in proof-of-concept trials.
    Pulkstenis E; Patra K; Zhang J
    J Biopharm Stat; 2017; 27(3):442-456. PubMed ID: 28166459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond p-values: A phase II dual-criterion design with statistical significance and clinical relevance.
    Roychoudhury S; Scheuer N; Neuenschwander B
    Clin Trials; 2018 Oct; 15(5):452-461. PubMed ID: 30204025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint.
    Huang B; Talukder E; Han L; Kuan PF
    J Biopharm Stat; 2019; 29(1):189-202. PubMed ID: 29969380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian Phase II optimization for time-to-event data based on historical information.
    Bertsche A; Fleischer F; Beyersmann J; Nehmiz G
    Stat Methods Med Res; 2019 Apr; 28(4):1272-1289. PubMed ID: 29284369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications of Bayesian analysis to proof-of-concept trial planning and decision making.
    Quan H; Chen X; Lan Y; Luo X; Kubiak R; Bonnet N; Paux G
    Pharm Stat; 2020 Jul; 19(4):468-481. PubMed ID: 31908134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian optimal phase II designs with dual-criterion decision making.
    Zhao Y; Li D; Liu R; Yuan Y
    Pharm Stat; 2023; 22(4):605-618. PubMed ID: 36871961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Joint probability of statistical success of multiple phase III trials.
    Zhang J; Zhang JJ
    Pharm Stat; 2013; 12(6):358-65. PubMed ID: 24106067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design considerations and analysis planning of a phase 2a proof of concept study in rheumatoid arthritis in the presence of possible non-monotonicity.
    Liu F; Walters SJ; Julious SA
    BMC Med Res Methodol; 2017 Oct; 17(1):149. PubMed ID: 28969588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASIED: a Bayesian adaptive subgroup-identification enrichment design.
    Xu Y; Constantine F; Yuan Y; Pritchett YL
    J Biopharm Stat; 2020 Jul; 30(4):623-638. PubMed ID: 31782938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A flexible multi-metric Bayesian framework for decision-making in Phase II multi-arm multi-stage studies.
    Dufault SM; Crook AM; Rolfe K; Phillips PPJ
    Stat Med; 2024 Feb; 43(3):501-513. PubMed ID: 38038137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flexible Bayesian subgroup analysis in early and confirmatory trials.
    Bunn V; Liu R; Lin J; Lin J
    Contemp Clin Trials; 2020 Nov; 98():106149. PubMed ID: 32942055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian Design of Proof-of-Concept Trials.
    Fisch R; Jones I; Jones J; Kerman J; Rosenkranz GK; Schmidli H
    Ther Innov Regul Sci; 2015 Jan; 49(1):155-162. PubMed ID: 30222466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decision-making in early clinical drug development.
    Frewer P; Mitchell P; Watkins C; Matcham J
    Pharm Stat; 2016 May; 15(3):255-63. PubMed ID: 26991401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of a Bayesian adaptive design in a proof of concept study.
    Smith MK; Jones I; Morris MF; Grieve AP; Tan K
    Pharm Stat; 2006; 5(1):39-50. PubMed ID: 17080927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian modeling and simulation to inform rare disease drug development early decision-making: Application to Duchenne muscular dystrophy.
    Lennie JL; Mondick JT; Gastonguay MR
    PLoS One; 2022; 17(4):e0247286. PubMed ID: 35482633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A decision-theoretic approach to Bayesian clinical trial design and evaluation of robustness to prior-data conflict.
    Calderazzo S; Wiesenfarth M; Kopp-Schneider A
    Biostatistics; 2022 Jan; 23(1):328-344. PubMed ID: 32735010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
    Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
    BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using phase II data for the analysis of phase III studies: An application in rare diseases.
    Wandel S; Neuenschwander B; Röver C; Friede T
    Clin Trials; 2017 Jun; 14(3):277-285. PubMed ID: 28387537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.
    Brannath W; Zuber E; Branson M; Bretz F; Gallo P; Posch M; Racine-Poon A
    Stat Med; 2009 May; 28(10):1445-63. PubMed ID: 19266565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advantages of a wholly Bayesian approach to assessing efficacy in early drug development: a case study.
    Walley RJ; Smith CL; Gale JD; Woodward P
    Pharm Stat; 2015; 14(3):205-15. PubMed ID: 25865949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.